'I'm here for breast cancer. Why are you talking to me about my heart?'

May 04, 2019

Milan, Italy - 4 May 2019: Many physicians are not telling cancer patients about the cardiotoxicity risks of treatments and may not be fully aware of the dangers themselves. A new study reveals an urgent need to look after the hearts of these patients. The research is presented today at EuroHeartCare 2019, a scientific congress of the European Society of Cardiology (ESC).1

"There was no mention that it could lead to heart disease. Would have been nice to know."

The growing number of cancer survivors and increasing number of over-65s needing chronic cancer therapy mean that the need for cardio-oncology services is rising. Heart failure caused by cancer therapy can occur up to 20 years after treatment. In 2012 over 32 million people worldwide were living with cancer.2

"Depending on the type of chemotherapy and radiotherapy, between 1% and 25% cancer patients may develop heart failure due to cancer treatment," said study author Professor Robyn Clark, of Flinders University, Adelaide, Australia. "Risk also depends on cardiovascular risk factors such as smoking and obesity. Better monitoring of the heart and intervention before, during and after treatment can prevent or lessen the impact of this cardiotoxicity."

The researchers reviewed medical records of 46 randomly selected cancer patients with cardiotoxicity who attended one of three hospitals between 1979 and 2015. Just 11% were referred to a cardiologist before chemotherapy and less than half (48%) were referred to a heart failure clinic after cancer treatment. Almost 40% were overweight or obese, 41% were current or ex-smokers, 24% were regular consumers of alcohol, 48% had hypertension, and 26% had diabetes.

In a subset of patients, practice was compared before (1994-2011) and after (2012-2015) the 2012 European Society for Medical Oncology guidelines were published.3 Referral to a cardiologist before chemotherapy rose from 0 to 23% and conducting a baseline echocardiogram of the heart increased from 57% to 77%.

Eleven patients were interviewed, of whom seven were involved in the medical records analysis. No patient could articulate their heart health needs. More than half said they started eating healthily after their cancer diagnosis yet appeared to lack understanding of a balanced diet.

The ESC published recommendations in 20164 and in 2018 launched the ESC Council of Cardio-Oncology to promote the prevention, early diagnosis, and management of cancer therapy-related cardiovascular diseases. Patients should be told the risks to their heart before starting cancer therapy, given help to quit smoking, eat healthily, exercise, and control their weight, and told to report signs and symptoms of cardiovascular disease.

Cardiotoxicity is detected using electrocardiogram (ECG), cardiac imaging, and biomarkers. The frequency of assessment depends on a number of factors - for example, evaluation for coronary artery disease, ischaemia and vascular disease is recommended in patients with a history of mediastinal radiation starting five years post-treatment and then at least every five years thereafter, even if they have no symptoms.

Angiotensin-converting enzyme (ACE) inhibitors or beta-blockers may be given to prevent or treat heart failure. And cancer therapy can be modified - for example reducing the dose or having a gap between two agents which raise heart failure risk when taken together (e.g. anthracyclines and trastuzumab).

"Monitoring the heart throughout the cancer journey can ensure it is protected," said Professor Clark. "Cardiotoxicity can occur even in people without cardiovascular risk factors since drugs like anthracyclines and trastuzumab are toxic to the heart, so it is an innocent bystander."

"For cancer patients who do develop heart failure, there are clinics that will improve their quality of life but our study shows many are not referred," she added. "Telephone calls to support and monitor those with cancer and heart failure would reduce the burden of hospital appointments, which patients said was a priority."
Authors: ESC Press Office
Tel: +33 (0)4 8987 2499
+33 (0) 7 8531 2036
Email: press@escardio.org
Follow us on Twitter @ESCardioNews

Notes to editor

The hashtag for EuroHeartCare 2019 is #euroheartcare.

Funding: This project was funded by a Heart Foundation Vanguard Grant (App ID: 100596- 2014). Professor Robyn A Clark is supported by a Heart Foundation Future Leader Fellowship (App ID:100847).

Disclosures: None.

References and notes

1The abstract 'Establishing a practice gap to inform the implementation of more effective cardio-oncology clinical services: a retrospective audit examining the clinical management of patients with cardiotoxicity' will be presented during Moderated poster session - Heart Failure on Saturday 4 May at 10:45 to 11:45 CEST in the Moderated Poster Area.


3Curigliano G, Cardinale D, Suter T, et al. Cardiovascular toxicity induced by chemotherapy, targeted agents and radiotherapy: ESMO Clinical Practice Guidelines. Ann Oncol. 2012;23 (Suppl 7):vii155-vii166. doi:10.1093/annonc/mds293.

4Zamorano JL, Lancellotti P, Rodriguez Muñoz D, et al. 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines. Eur Heart J. 2016;37:2768-2801. doi:10.1093/eurheartj/ehw211.

About the Association of Cardiovascular Nursing & Allied Professions

The mission of the Association of Cardiovascular Nursing & Allied Professions (ACNAP) is to support nurses and allied health professionals throughout Europe to deliver the best possible care to patients with cardiovascular disease and their families.

About EuroHeartCare

EuroHeartCare is the annual Congress of the Association of Cardiovascular Nursing & Allied Professions (ACNAP) of the European Society of Cardiology (ESC).

About the European Society of Cardiology

The European Society of Cardiology brings together health care professionals from more than 150 countries, working to advance cardiovascular medicine and help people lead longer, healthier lives.

Information for journalists attending EuroHeartCare 2019

EuroHeartCare 2019 will be held 2 to 4 May at the Milano Convention Centre (MiCo) in Milan, Italy. Explore the scientific programme.

European Society of Cardiology

Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.